Free Trial

Century Therapeutics Q3 2023 Earnings Report

Century Therapeutics logo
$0.90 -0.01 (-1.33%)
As of 04:00 PM Eastern

Century Therapeutics EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.53
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Century Therapeutics Revenue Results

Actual Revenue
$0.15 million
Expected Revenue
$1.08 million
Beat/Miss
Missed by -$930.00 thousand
YoY Revenue Growth
N/A

Century Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Century Therapeutics Earnings Headlines

A simple pattern that works in any market
Right when most traders were getting bearish, The All-Weather Pattern signaled something different. Following this setup could've turned every $1,000 into $1,770 in just 48 hours. But here's what really gets me excited... You don't need to be glued to your screen all day, no complex formulas, no guessing. Just wait for a stock to close below The All-Weather Pattern, then check if it opens higher the next morning. That's it. While of course I cannot promise future returns or against losses… I've put together a complete breakdown of how this works, including the new stock that’s tending towards The All-Weather Pattern this week.
Century Therapeutics price target lowered to $4 from $12 at Piper Sandler
See More Century Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email.

About Century Therapeutics

Century Therapeutics (NASDAQ:IPSC), a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

View Century Therapeutics Profile

More Earnings Resources from MarketBeat